{
    "organizations": [],
    "uuid": "a67e6bd85d78daad20ebe5b97e9eee961bab9ab1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-says-phase-iii-data-for-b/brief-novartis-says-phase-iii-data-for-brolucizumab-demonstrate-reliability-of-12-week-treatment-interval-idUSFWN1S719P",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis Says Phase III Data For Brolucizumab Demonstrate Reliability Of 12-Week Treatment Interval",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Novartis AG:\n* PHASE III DATA FOR BROLUCIZUMAB DEMONSTRATE RELIABILITY OF 12-WEEK TREATMENT INTERVAL\n* NOVARTIS- PATIENTS FOR BROLUCIZUMAB 12-WEEK TREATMENT IN PHASE III HAWK AND HARRIER TRIALS HAD 87% AND 83% PROBABILITY OF CONTINUING 12-WEEK INTERVAL THROUGH WEEK 48\n* BROLUCIZUMAB SAFETY WAS COMPARABLE TO AFLIBERCEPT WITH OVERALL INCIDENCE OF ADVERSE EVENTS BALANCED ACROSS ALL TREATMENT GROUPS IN BOTH STUDIES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-01T04:11:00.000+03:00",
    "crawled": "2018-05-01T00:23:29.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "novartis",
        "ag",
        "phase",
        "iii",
        "data",
        "brolucizumab",
        "demonstrate",
        "reliability",
        "treatment",
        "interval",
        "patient",
        "brolucizumab",
        "treatment",
        "phase",
        "iii",
        "hawk",
        "harrier",
        "trial",
        "probability",
        "continuing",
        "interval",
        "week",
        "brolucizumab",
        "safety",
        "comparable",
        "aflibercept",
        "overall",
        "incidence",
        "adverse",
        "event",
        "balanced",
        "across",
        "treatment",
        "group",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}